Search Results for "Rituximab Patent"

17:47 EDT 26th July 2016 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...


India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Celltrion Expects Korea Rituximab Approval Despite Biogen Action

Biogen moves to halt Celltrion from selling a rituximab biosimilar in South Korea by seeking a patent scope confirmation trial as the South Korean firm gears up to launch its second biosimilar. But Ce...

EMA Accepts Submission for Rituximab Biosimilar

​Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche...

Rituximab biosimilar shows pharmacokinetic bioequivalence in patients with RA

GP2013, a proposed rituximab biosimilar, demonstrated pharmacokinetic bioequivalence to rituximab in patients with rheumatoid arthritis, according to results presented at the EULAR Annual Congress.Res...

Rituximab for Thrombotic Thrombocytopenic Purpura

Adding rituximab to plasma exchange and steroids improved relapse-free survival in a nonrandomized trial.

Rituximab decreased disease activity in patients with severe or refractory SLE

Treatment of systemic lupus erythematosus with rituximab effectively decreased disease activity with a low incidence of adverse effects in patients with severe or refractory disease, according to resu...

Rituximab plus Dose-Dense Chemotherapy for Burkitt Lymphoma

High response and cure rates were achieved by adding rituximab to multiagent induction chemotherapy.

The BAFFling effects of rituximab in lupus: danger ahead?

Ehrenstein and Wing assert that rituximab re-treatment can trigger a vicious circle of ever-rising levels of BAFF (B-cell-activating factor, also known as TNF ligand superfamily member 13B), increasin...

EU approves Roche's subcutaneous rituximab for CLL

Roche Holding's subcutaneous formulation of MabThera, or rituximab, was granted approval by the European Commission for previ -More- 

Matching PubMed Articles

Patent Highlights June-July 2015.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Searching bioremediation patents through Cooperative Patent Classification (CPC).

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing wi...

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.

Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with in...

Is rituximab sub-optimally dosed in indolent B cell lymphoma?

Rituximab pharmacokinetics are affected by gender, age and weight and can affect outcomes in aggressive B cell lymphoma. Less is known about the pharmacokinetics of rituximab in indolent B cell lympho...

Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia.

Rituximab in combination with chemotherapy is an effective treatment of patients (pts) with chronic lymphocytic leukemia (CLL). The most frequent adverse event of rituximab is infusion-related toxicit...

Search Whole site using Google

Quick Search
Advertisement Advertisement